Physician profile
Vidal Primiterio
NPI 1861472987
$22,225.02
in general payments reported to CMS, 2019-2025
48 companies · $4,786 in 2025
The $4,786 reported for 2025 was more than what 98% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $4,140 · 2022: $4,306 · 2023: $4,745 · 2024: $4,248 · 2025: $4,786.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $14K · Education: $104.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $13,674.55 |
| Education | $104.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $3,506.84 | 2021-2025 | Farxiga, Breztri, Airsupra |
| Abbvie INC. | $2,545.06 | 2021-2025 | |
| Pfizer INC. | $1,530.73 | 2021-2025 | |
| Amgen INC. | $1,363.48 | 2021-2025 | Repatha, Otezla, Evenity |
| Novo Nordisk INC | $1,228.64 | 2021-2025 | Rybelsus, Ozempic |
| Bayer Healthcare Pharmaceuticals INC. | $1,119.15 | 2022-2025 | |
| Janssen Pharmaceuticals, INC | $980.33 | 2021-2024 | Xarelto |
| Glaxosmithkline, LLC. | $975.82 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $723.53 | 2021-2025 | Jardiance, Mounjaro, Zepbound |
| Astellas Pharma US INC | $687.24 | 2021-2025 | Veozah, Myrbetriq |
| Novartis Pharmaceuticals Corporation | $590.74 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $498.11 | 2021-2023 | Belsomra |
| Biohaven Pharmaceuticals, INC. | $421.26 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $417.42 | 2021-2025 | Xifaxan |
| Redhill Biopharma INC. | $415.20 | 2021-2022 |
Show all 48 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $406.91 | 2023-2025 | Freestyle Libre 3 |
| Sumitomo Pharma America, INC. | $403.01 | 2023-2025 | Gemtesa |
| Otsuka America Pharmaceutical, INC. | $353.92 | 2023-2025 | Rexulti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $348.67 | 2021-2025 | Jardiance, Spiriva Respimat |
| Phathom Pharmaceuticals, INC. | $331.05 | 2024-2025 | Voquezna |
| Exact Sciences Corporation | $327.66 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Sanofi-Aventis U.S. LLC | $315.11 | 2022-2023 | |
| Ardelyx, INC. | $301.78 | 2023-2025 | Ibsrela |
| Shield Therapeutics INC | $249.49 | 2023-2024 | Accrufer |
| E.R. Squibb & Sons, L.L.C. | $230.41 | 2021-2025 | Eliquis, Camzyos |
| Corcept Therapeutics | $224.01 | 2025 | Korlym |
| Paratek Pharmaceuticals, INC. | $203.24 | 2022-2025 | Nuzyra |
| Esperion Therapeutics, INC. | $192.15 | 2021-2025 | Nexletol |
| Biohaven Pharmaceutical Holding Company LTD. | $176.49 | 2022 | |
| Lundbeck LLC | $175.20 | 2023-2025 | Rexulti |
| Nestle Healthcare Nutrition INC. | $127.37 | 2021-2022 | |
| Xeris Pharmaceuticals, INC. | $124.03 | 2023-2025 | Gvoke Hypopen |
| Inspire Medical Systems, INC. | $97.31 | 2024-2025 | Inspire |
| Viiv Healthcare Company | $97.08 | 2021-2024 | Dovato |
| Dexcom, INC. | $70.03 | 2023-2025 | Dexcom G6 Transmitter |
| Viatris Specialty LLC | $69.38 | 2025 | Yupelri |
| Takeda Pharmaceuticals U.S.A., INC. | $53.29 | 2021-2022 | |
| Aimmune Therapeutics, INC. | $51.17 | 2025 | Zenpep, Vowst |
| Teva Pharmaceuticals USA, INC. | $45.69 | 2021 | |
| Ironwood Pharmaceuticals, INC | $39.68 | 2022-2023 | Linzess |
| Genentech USA, INC. | $39.56 | 2021-2022 | |
| Amarin Pharma, INC. | $34.46 | 2022 | |
| Qol Medical, LLC | $34.05 | 2024 | Sucraid |
| Scpharmaceuticals INC. | $29.32 | 2025 | |
| Vertex Pharmaceuticals Incorporated | $20.13 | 2025 | |
| Cequr Corporation | $18.45 | 2025 | Cequr Simplicity |
| Idorsia Pharmaceuticals US INC | $16.27 | 2022 | |
| Hologic Sales and Service, LLC | $15.10 | 2025 | Thinprep 2000 Processor, Aptima |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vidal Primiterio listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.